CHARLOTTESVILLE, Va. (CBS19 NEWS) -- The Food and Drug Administration approved a second Alzheimer’s medication that appears to slow the disease’s progression in its early stages. 

Alzheimer’s disease is the leading cause of death in the United States, affecting more than six million Americans. This medication could help those with Alzheimer's to live a normal life. 

In a current study of the medicine Lecanemab, asymptomatic patients are taking it in hopes of getting ahead of the disease.

“What that means is if that clinical trial actually is safe and shows efficacy in being able to decrease the amount of amyloid plaque in the brain, this may be our first opportunity to impact Alzheimer’s before people even experience memory loss,” said Katie McDonough, the Community Executive Director of the Alzheimer’s Association Southeastern Virginia chapter.

To get involved with these trials, you can find more information at

The Alzheimer’s Association submitted a request to remove requirements for Medicare beneficiaries so that more people will be able to receive the drug.

At this time, no insurance is covering the cost of this treatment, which means that access is limited to those who can afford to pay out-of-pocket. But the Alzheimer’s Association hopes to get it approved soon.